Semaglutide

A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.

Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.

TouchREVIEWS in endocrinology|2023|Berman C, Vidmar A, Chao L|17 citations

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained traction for the management of type 2 diabetes and obesity. Unlike several classes of antidiabetic medications that contribute to weight gain, GLP-1RAs not only reduce haemoglobin A1c,…

Review

PMID: 37313232

Semaglutide: a new drug for the treatment of obesity.

Drug and therapeutics bulletin|2023|Lexchin J, Mintzes B|15 citations

Semaglutide (▼Ozempic solution for injection, ▼Rybelsus tablets-Novo Nordisk) was initially granted market authorisation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In 2021 and 2022, regulatory agencies in the USA and Eur…

Review

PMID: 37879878

Boosting systemic absorption of peptides with a bioinspired buccal-stretching patch.

Science translational medicine|2023|Luo Z et al.|36 citations

Biopharmaceuticals, including proteins and peptides, have revolutionized the treatment of a wide range of diseases, from diabetes and cardiovascular disorders to virus infections and cancer. Despite their efficacy, most of these macromolecular drugs…

PMID: 37756378

Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.

Annals of medicine|2023|Patel T et al.|11 citations

BACKGROUND: The emergence of genetically-modified human proteins and glucagon-like peptide-1 (GLP-1) receptor agonists have presented a promising strategy for effectively managing diabetes. Due to the scarcity of clinical trials focusing on the safet…

ReviewMeta-Analysis

PMID: 37498865

In brief: Semaglutide (Wegovy) for weight loss in children.

The Medical letter on drugs and therapeutics|2023|Unknown authors|1 citation

PMID: 36757837

Subcutaneous Semaglutide Use for Weight Management: Practice and Attitudes of Physicians in Israel.

The Israel Medical Association journal : IMAJ|2023|Dicker D et al.|4 citations

BACKGROUND: In 2019, 1 mg subcutaneous semaglutide was registered for the treatment of diabetes in Israel. Recognition of its effect on weight has led to its use as a treatment for obesity. OBJECTIVES: To explore physicians' pre-therapy consideration…

PMID: 37846993

Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials.

Frontiers in pharmacology|2023|Gu Y et al.|27 citations

The relative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and 4 glucagon-like peptide-1 (GLP-1) receptor agonists for non-alcoholic fatty liver disease (NAFLD) therapy has not been sufficiently investigated.Randomized cont…

Review

PMID: 36992825

Corrigendum: GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.

Frontiers in endocrinology|2023|Zhang Z et al.|4 citations

[This corrects the article DOI: 10.3389/fendo.2023.1149328.].

PMID: 37900146

Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment.

International journal of obesity (2005)|2023|Stenberg E, Näslund E|25 citations

BACKGROUND: Glucagon-like Peptide-1 receptor agonists (GLP-1 RA) and metabolic and bariatric surgery (MBS) both improve cardiovascular outcomes in patients with severe obesity and type-2 diabetes (T2D). The aim of the present study was to assess the…

PMID: 36670155

Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?

Metabolism: clinical and experimental|2022|Valenzuela-Vallejo L, Guatibonza-García V, Mantzoros C|36 citations

Non-Alcoholic Fatty Liver Disease (NAFLD) is a highly prevalent disease and unmet clinical need that we have recently proposed to be renamed for simplicity and accuracy as Fatty Liver Disease (FLD), with specific subclassifications. It has been commo…

PMID: 35803320

The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice.

Clinics and research in hepatology and gastroenterology|2022|Reis-Barbosa P et al.|39 citations

PURPOSE: The liver regulates lipid metabolism. Decreasing mTOR (mechanistic target of rapamycin complex 1) and enhancing AMPK (AMP-activated protein kinase) help degrade hepatic diet-induced accumulated lipids. Therefore, the glucagon-like peptide ty…

Animal Study

PMID: 35427802

Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.

The New England journal of medicine|2022|Patoulias D, Papadopoulos C, Doumas M|1 citation

PMID: 35172065

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.

Frontiers in public health|2022|Shu Y et al.|89 citations

BACKGROUND: Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM) and chronic weight management in obesity or overweight adults. However, real-world data regarding its long-term gastrointestinal safety and tolerability in large sa…

PMID: 36339230

GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models.

European journal of pharmacology|2022|Zhang M et al.|5 citations

GZR18 is a novel analog of glucagon-like peptide-1 (GLP-1). This study evaluates the pharmacology, pharmacokinetics, and efficacy of GZR18, and its potential for the treatment of Type 2 diabetes mellitus (T2DM). In vitro pharmacology and activity of…

Animal StudyIn Vitro

PMID: 35718129

GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.

Peptides|2022|Mayendraraj A, Rosenkilde M, Gasbjerg L|112 citations

Glucagon-like peptide 1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) are two class B1 G protein-coupled receptors, which are stimulated by the gastrointestinal hormones GLP-1 and GIP, respectively. In the pancrea…

ReviewAnimal Study

PMID: 35065096

A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form.

Indian journal of endocrinology and metabolism|2022|Kalra S, Das S, Zargar A|6 citations

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have gained an important place in the management of diabetes management because of their exceptional glucose-lowering, weight lowering and cardiovascular (CV) benefits. Despite recommendations by v…

Review

PMID: 35873937

Discovery of once-weekly, peptide-based selective GLP-1 and cholecystokinin 2 receptors co-agonizts.

Peptides|2022|Zhou F et al.|4 citations

A group of long-acting, peptide-based, and selective GLP-1R/CCK-2R dual agonizts were identified by rational design. Guided by sequence analysis, structural elements of the CCK-2R agonist moiety were engineered into the GLP-1R agonist Xenopus GLP-1,…

Animal Study

PMID: 35594964

Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.

Current obesity reports|2022|Polyzos S et al.|31 citations

PURPOSE OF REVIEW: Obesity is closely associated with nonalcoholic fatty liver disease (NAFLD), a highly prevalent disease without any approved medication. The aim of this review was to summarize the evidence on the effect of anti-obesity medications…

Review

PMID: 35501557

[Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].

Revue medicale suisse|2022|Scheen A, Radermecker R, Paquot N|3 citations

Tirzepatide is a unimolecular dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which is developed as once-weekly injection for the treatment of type 2 diabetes. Because of the comp…

Randomized Controlled Trial

PMID: 36004653

A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study.

Advances in therapy|2022|Romera I et al.|7 citations

INTRODUCTION: The REPRESENT study aims to examine whether participants enrolled in glucagon-like peptide 1 receptor agonist cardiovascular outcome trials (CVOTs) LEADER (liraglutide), REWIND (dulaglutide), and SUSTAIN-6 (injectable semaglutide) are r…

Observational

PMID: 35689162

Studies

Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.

Semaglutide: a new drug for the treatment of obesity.

Boosting systemic absorption of peptides with a bioinspired buccal-stretching patch.

Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis.

In brief: Semaglutide (Wegovy) for weight loss in children.

Subcutaneous Semaglutide Use for Weight Management: Practice and Attitudes of Physicians in Israel.

Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials.

Corrigendum: GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.

Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment.

Recent guidelines for Non-Alcoholic Fatty Liver disease (NAFLD)/ Fatty Liver Disease (FLD): Are they already outdated and in need of supplementation?

The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice.

Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.

GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models.

GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.

A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form.

Discovery of once-weekly, peptide-based selective GLP-1 and cholecystokinin 2 receptors co-agonizts.

Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.

[Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].

A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study.